Item analyses of the 20-item prosopagnosia index using classical test theory and item response theory.

Obesity is a complex condition associated with many chronic diseases [–]. Obesity has also been associated with a reduction in disease-free life (ranging from 3–8 years) [] and with an estimated 1.3-fold higher risk of early death compared to individuals with healthy body weight [–]. Modest body weight reductions of 5% may lessen or resolve certain obesity-related complications []. In the Look AHEAD study, body weight reductions of 5% to <10% significantly improved glycemic control, lipid levels, and blood pressure in participants with obesity and without type 2 diabetes, and even greater odds of improving cardiovascular risk factors were observed in individuals who achieved 10–15% body weight reduction []. As the prevalence of obesity continues to rise, targeted pharmacotherapy in addition to lifestyle modification has become more pertinent to the management of chronic, excess body weight. Tirzepatide is a once weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and obesity, among other indications. In the SURMOUNT clinical trial program, tirzepatide treatment at all doses studied (5 mg, 10 mg, or 15 mg or the maximum tolerated dose [MTD] of 10 mg or 15 mg) resulted in robust and clinically meaningful reductions in body weight ranging from 13–26%, with 82–99% of participants achieving body weight reduction thresholds of ≥5% over a period of 72 or 88 weeks in the respective studies [–]. Furthermore, significant reductions in systolic blood pressure of up to 11 mmHg and non-high-density lipoprotein cholesterol (non-HDL-C) of up to 13% were observed with tirzepatide compared with placebo [–], suggesting improved cardiometabolic health beyond the observed body weight reduction.